MHRA Clarifies Licensing for Microbiome-Based Medicines
The MHRA has set out its position on microbiome-based medicinal products, confirming that a clear UK licensing route already exists for these therapies.
What the First FDA AI Warning Letter Means for Pharma
The FDA’s first AI warning letter shows Purolea Cosmetics Lab used AI to draft CGMP documents unchecked. Here’s what pharma manufacturers must learn now.
ICH M12 Drug Interaction Studies: EMA Targets the Gut Gap
The EMA’s draft guideline extends ICH M12 drug interaction studies to the gut. See what it asks on food effect, gastric pH, and excipients, and how to respond.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
Next-Generation Sequencing for Cell Line Development in Biologics Manufacturing
Discover how next-generation sequencing in cell line development is improving biologics manufacturing, quality control, and regulatory confidence.
Cold Chain Optimisation by Rethinking Pharma Logistics
See how cold chain optimisation can reduce pharmaceutical logistics costs, emissions, and product risk by modelling uncertainty across storage and distribution.